Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence

Author(s): Simone Ronsisvalle, Federica Panarello, Rosaria Di Mauro, Renato Bernardini, Giovanni Li Volti* and Giuseppina Cantarella

Volume 27, Issue 10, 2021

Published on: 09 December, 2020

Page: [1323 - 1329] Pages: 7

DOI: 10.2174/1381612826666201210092736

Abstract

Background: The evolution of the pandemic has burdened the national healthcare systems worldwide and at present, there is no preferred antiviral treatment for COVID-19. Recently, the SARS-Cov-2 protease structure was released that may be exploited in in-silico studies in order to conduct molecular docking analysis.

Methods: In particular, we compared the binding of twoantimalarial drugs, already in use, (i.e. chloroquine and hydroxychloroquine), which showed some potential clinical effects on COVID-19 patients, using ritonavir, lopinavir and darunavir as positive control tree antiviral recognized compounds.

Results: Our results showed that hydroxychloroquine but not chloroquine exhibited a significant binding activity to the main protease similar to that possessed by protease inhibitors tested for other viral infections.

Conclusion: Our data suggest that hydroxychloroquine may exert additional direct antiviral activity compared to chloroquine. In the absence of clinical studies comparing the efficacy of these two compounds, hydroxychloroquine may offer additional effects and may be considered as the first choice.

Keywords: COVID19, protease inhibitor, SARS-CoV-2, computational analysis, Anti-malarial, hydroxychloroquine.

« Previous
[1]
Ryu S, Chun BC. Korean Society of Epidemiology 2019-nCoV Task Force Team. An interim review of the epidemiological characteristics of 2019 novel coronavirus. Epidemiol Health 2020; 42e2020006
[http://dx.doi.org/10.4178/epih.e2020006] [PMID: 32023775]
[2]
de Alwis R, Chen S, Gan ES, Ooi EE. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine 2020; 55102768
[http://dx.doi.org/10.1016/j.ebiom.2020.102768] [PMID: 32344202]
[3]
Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report. Chest 2020; 158(1): e15-9.
[http://dx.doi.org/10.1016/j.chest.2020.04.024]
[4]
Rossi JJ, Rossi D. Oligonucleotides and the COVID-19 pandemic: A perspective. Nucleic Acid Ther 2020; 30(3): 129-32.
[http://dx.doi.org/10.1089/nat.2020.0868] [PMID: 32297843]
[5]
Han Y, Král P. Computational design of ACE2-based peptide inhibitors of sars-cov-2. ACS Nano 2020; 14(4): 5143-7.
[http://dx.doi.org/10.1021/acsnano.0c02857] [PMID: 32286790]
[6]
Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV-2: Recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem 2020; 27(27): 4536-41.
[http://dx.doi.org/10.2174/0929867327666200416131117] [PMID: 32297571]
[7]
Patsner B. Invasive adenocarcinoma of the ovary diagnosed after cardiac transplantation. A case report. J Reprod Med 1988; 33(2): 239-41.
[PMID: 3280789]
[8]
Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020; 177104762
[http://dx.doi.org/10.1016/j.antiviral.2020.104762] [PMID: 32147496]
[9]
Frisk-Holmberg M, Bergqvist Y, Englund U. Chloroquine intoxication. Br J Clin Pharmacol 1983; 15(4): 502-3.
[http://dx.doi.org/10.1111/j.1365-2125.1983.tb01540.x] [PMID: 6849790]
[10]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[11]
Garcia-Cremades M, Solans BP, Hughes E, et al. Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing. Clin Pharmacol Ther 2020; 108(2): 253-63.
[http://dx.doi.org/10.1002/cpt.1856] [PMID: 32285930]
[12]
Hashem AM, Alghamdi BS, Algaissi AA, et al. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel Med Infect Dis 2020; 35101735
[http://dx.doi.org/10.1016/j.tmaid.2020.101735] [PMID: 32387694]
[13]
Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health 2020; 8(5): e639-40.
[http://dx.doi.org/10.1016/S2214-109X(20)30114-5] [PMID: 32199468]
[14]
Cheeseright T, Mackey M, Rose S, Vinter A. Molecular field extrema as descriptors of biological activity: definition and validation. J Chem Inf Model 2006; 46(2): 665-76.
[http://dx.doi.org/10.1021/ci050357s] [PMID: 16562997]
[15]
DA Case KB, IY Ben-Shalom, SR Brozell, DS et al AMBER20 California Uo, ed^eds: San Francisco . 2020.
[16]
Phillips JC, Hardy DJ, Maia JDC, et al. Scalable molecular dynamics on CPU and GPU architectures with NAMD. J Chem Phys 2020; 153(4)044130
[http://dx.doi.org/10.1063/5.0014475] [PMID: 32752662]
[17]
Chen YW, Yiu CB, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000 Res 2020; 9: 129.
[http://dx.doi.org/10.12688/f1000research.22457.2] [PMID: 32194944]
[18]
Bauer MR, Mackey MD. Electrostatic complementarity as a fast and effective tool to optimize binding and selectivity of protein-ligand complexes. J Med Chem 2019; 62(6): 3036-50.
[http://dx.doi.org/10.1021/acs.jmedchem.8b01925] [PMID: 30807144]
[19]
Muramatsu T, Takemoto C, Kim YT, et al. SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity. Proc Natl Acad Sci USA 2016; 113(46): 12997-3002.
[http://dx.doi.org/10.1073/pnas.1601327113] [PMID: 27799534]
[20]
Hsu MF, Kuo CJ, Chang KT, et al. Mechanism of the maturation process of SARS-CoV 3CL protease. J Biol Chem 2005; 280(35): 31257-66.
[http://dx.doi.org/10.1074/jbc.M502577200] [PMID: 15788388]
[21]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-80.
[22]
Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am J Emerg Med 2020; 38(7): 1488-93.
[http://dx.doi.org/10.1016/j.ajem.2020.04.035] [PMID: 32336586]
[23]
Choy KT, Wong AY, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res 2020; 178104786
[http://dx.doi.org/10.1016/j.antiviral.2020.104786] [PMID: 32251767]
[24]
Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003; 9(6): 399-406.
[PMID: 14660806]
[25]
Inglot AD. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J Gen Virol 1969; 4(2): 203-14.
[http://dx.doi.org/10.1099/0022-1317-4-2-203] [PMID: 4306296]
[26]
Miller DK, Lenard J. Antihistaminics, local anesthetics, and other amines as antiviral agents. Proc Natl Acad Sci USA 1981; 78(6): 3605-9.
[http://dx.doi.org/10.1073/pnas.78.6.3605] [PMID: 6115382]
[27]
Shimizu Y, Yamamoto S, Homma M, Ishida N. Effect of chloroquine on the growth of animal viruses. Arch Gesamte Virusforsch 1972; 36(1): 93-104.
[http://dx.doi.org/10.1007/BF01250299] [PMID: 4335025]
[28]
Hossen MS, Barek MA, Jahan N, Safiqul Islam M. A review on current repurposing drugs for the treatment of COVID-19: Reality and challenges. SN Compr Clin Med 2020; pp. 1-13.
[29]
Verdugo-Paiva F, Izcovich A, Ragusa M, Rada G. Lopinavir-ritonavir for COVID-19: A living systematic review. Medwave 2020; 20(6)e7967
[http://dx.doi.org/10.5867/medwave.2020.06.7966] [PMID: 32678815]
[30]
Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004; 323(1): 264-8.
[http://dx.doi.org/10.1016/j.bbrc.2004.08.085] [PMID: 15351731]
[31]
Tan YW, Yam WK, Sun J, Chu JJH. An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease. Antiviral Res 2018; 149: 143-9.
[http://dx.doi.org/10.1016/j.antiviral.2017.11.017] [PMID: 29175128]
[32]
Keyaerts E, Li S, Vijgen L, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 2009; 53(8): 3416-21.
[http://dx.doi.org/10.1128/AAC.01509-08] [PMID: 19506054]
[33]
Li C, Zhu X, Ji X, et al. Chloroquine, a FDA-approved drug, prevents zika virus infection and its associated congenital microcephaly in mice. EBioMedicine 2017; 24: 189-94.
[http://dx.doi.org/10.1016/j.ebiom.2017.09.034] [PMID: 29033372]
[34]
Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis 2011; 11(9): 677-83.
[http://dx.doi.org/10.1016/S1473-3099(11)70065-2] [PMID: 21550310]
[35]
Tricou V, Minh NN, Van TP, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 2010; 4(8)e785
[http://dx.doi.org/10.1371/journal.pntd.0000785] [PMID: 20706626]
[36]
Connolly KM, Stecher VJ, Danis E, Pruden DJ, LaBrie T. Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying antirheumatic drugs. Agents Actions 1988; 25(1-2): 94-105.
[http://dx.doi.org/10.1007/BF01969100] [PMID: 3142230]
[37]
Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol 2011; 23(3): 278-81.
[http://dx.doi.org/10.1097/BOR.0b013e32834456bf] [PMID: 21448012]
[38]
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003; 3(11): 722-7.
[http://dx.doi.org/10.1016/S1473-3099(03)00806-5] [PMID: 14592603]
[39]
Roques P, Thiberville SD, Dupuis-Maguiraga L, et al. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses 2018; 10(5): 10.
[http://dx.doi.org/10.3390/v10050268] [PMID: 29772762]
[40]
Chauhan A, Tikoo A. The enigma of the clandestine association between chloroquine and HIV-1 infection. HIV Med 2015; 16(10): 585-90.
[http://dx.doi.org/10.1111/hiv.12295] [PMID: 26238012]
[41]
Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71(15): 732-9.
[http://dx.doi.org/10.1093/cid/ciaa237] [PMID: 32150618]
[42]
Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6: 16.
[http://dx.doi.org/10.1038/s41421-020-0156-0] [PMID: 32194981]
[43]
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1): 72-3.
[http://dx.doi.org/10.5582/bst.2020.01047] [PMID: 32074550]
[44]
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020; 57: 279-83.
[http://dx.doi.org/10.1016/j.jcrc.2020.03.005] [PMID: 32173110]
[45]
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56(1)105949
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
[46]
Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis 2020; 34101663
[http://dx.doi.org/10.1016/j.tmaid.2020.101663] [PMID: 32289548]
[47]
Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med 2020; 8(6): 539-41.
[http://dx.doi.org/10.1016/S2213-2600(20)30172-7] [PMID: 32304640]

Rights & Permissions Print Cite
Article Metrics
26
1
© 2024 Bentham Science Publishers | Privacy Policy